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Abstract
Much has been said and published in the past years about new approaches to coagulation  
management in acquired bleeding disorders. This is particularily true in the perioperative 
setting and in trauma induced coagulopathy, which are associated with severe bleeding and 
massive blood transfusion rates that might have deletirious effects, such as incresead morbidity 
and mortality.
Our current understanding of hemostasis and new diagnostic tools such as thromboelastog-
raphy and rotational thromboelastometry (point-of-care tests) offer insight into the in vivo 
processes ongoing in a bleeding patient. It has been demonstrated that when a patient bleeds, 
fibrinogen is the first coagulation factor to reach really low levels, insufficient for formation of  
a clot. Management of massive blood loss may also require the administration of other coagula-
tion factors like those present in Prothrombin complex concentrates (PCC) and plasma. 
In resume, the overall use of factor concentrates for management of acquired bleeding disorders 
has gradually increased during the last several years, mainly that of fibrinogen concentrate. 
Parallel to this trend we observe the reduction in the number of transfusions of fresh frozen 
plasma (FFP) and other blood components.
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Introduction
Much has been said and published in the 
past years about new approaches to coagulation 
management in acquired bleeding disorders. This is 
particularily true in perioperative setting and trau-
ma induced coagulopathy associated with severe 
bleeding and higher blood transfusion rates [1]. 
In Portugal as in other countries, these situ-
ations are a matter of great concern, particularily 
because massive blood tranfusions are associated 
with risks such as increased morbility and mortality 
[2]. The current trend in the management of coagu-
lopathic patients is therefore to seek alternatives 
to blood components, in particular clotting factor 
concentrates.
The aim of this paper is to explain the scientific 
rationale that justifies the benefits of using factor 
concentrates in these situstions and to present the 
state of the art in this situations. Reference to the 
current situation in Portugal is made throughout 
the text. 
Hemostasis
The Y-shaped cascade model of coagulation 
was proposed in the 1960s by different groups 
of investigators after decades of research on the 
hemostatic mechanism. In this model enzymes 
cleave proenzymes to generate the next enzyme 
in the cascade. Finally this leads to the formation 
of a fibrin network and then to the generation of 
a stable haemostatic clot (Figure 1).
The coagulation cascade process was split 
into two pathways: the extrinsic and the intrinsic 
pathway. Both of them activate factor X to factor Xa; 
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the latter in turn activates prothrombin to 
thrombin, which then cleaves fibrinogen to form 
fibrin [3]. 
The cascade model is extremely helpful for 
the understanding of the coagulation enzymatic 
steps and provides an adequate explanation of the 
sequence of events in a static system where blood 
does not interact with vascular wall or cell surfaces. 
This model may also suggest that the extrinsic and 
intrinsic pathways operate independently whereas 
clinical manifestations in patients with congenital 
factor deficiencies contradict this concept [3]. 
The coagulation cascade model therefore does 
not adequately explain the mechanisms leading to 
hemostasis in vivo.
The currently developed model of hemostasis 
replaces the classical model of coagulation cascade 
and takes into account the vital role of blood com-
ponents such as platelets and microparticles in 
blood coagulation processes, because the speed at 
which enzymatic reactions proceed are to a large 
extent affected by the presence of a viable cell 
membrane. The generation of thrombin, which is 
essential for this process, occurs directly on the 
activated platelet surface, and both pathways are 
parallel generators of FXa. The cell-based model 
of coagulation provides four distinct phases: initia-
tion, amplification, propagation and stabilization [3]. 
In primary hemostasis which immediately follows 
vascular injury, collagen and other substrates 
Figure 1. The coagulation cascade in its classical Y-shape (adapted by: Gailani D. & Renn T. 2007; Mackman N. 2007; 
Tortora G.J., Derrickson B. 2006; Synapse B.V. 2009; Keularts I.M. 2001; Monroe D.M. & Hoffman 2005)
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are exposed to blood flow and platelets adhere to 
them, through von Willebrand factor (VWF), which 
binds both to collagen and to specific receptor on 
the platelet surface. During adhesion, platelets 
become activated, they change shape, undergo 
degranulation, spread over the damaged endothe-
lium and release several substances, which recruit 
more platelets to the growing mass and promote 
aggregation [4].
The cell-based model of coagulation focuses on 
the interaction between coagulation factors and the 
cell surface of activated platelets. Through the four 
phases of secondary hemostasis thrombin is pro-
gressively generated until the phase of propagation 
is reached. Now the bleeding patient has sufficient 
amount of thrombin to convert fibrinogen into fibrin, 
but it is FXIII that leads to the formation of a really 
mechanically stable clot through cross linking and 
stabilization. Finally, the bleeding is arrested and the 
process of wound healing begins (Figure 2).
Given the above facts one may speculate 
that requirements for transfusion in a bleeding 
patient may be different and specific for the mo-
ment. The so called bedside point of care tests 
like thromboelastography and rotational throm-
boelastometry [5] facilitate prompt and accurate/ 
/adequate diagnosis for such specific requirements 
in situation of trauma [6], in the operating room 
setting [7] or the Intensive Care Unit. These con-
cepts came in a time with the growing awareness 
of risks associated with the transfusion of blood 
components in both health-care professionals and 
patients. Therefore it can be said that during the 
last decades the understanding of the haemostatic 
system has undergone major revisions, and the 
therapeutic choices have also shifted to specific 
plasma factor concentrates. The above is true for 
many countries in Europe including Portugal where 
the use of clotting factor concentrates mainly that 
of fibrinogen concentrate and prothrombin complex 
concentrate has increased during the last several 
years. The parallel trend observed is a reduction in 
the number of transfusions of Fresh Frozen Plasma 
(FFP) and other blood components.
Clotting factor concentrates
Fibrinogen
Fibrinogen is a 340 KDa glycoprotein, synthe-
sized in the liver and present in blood plasma at 
a concentration of 2.0 to 4.5 g/L as measured by 
the Clauss method [8]. In a bleeding patient, the 
levels of fibrinogen depend on the balance between 
syntheses, use, and consumption [9]. It has been 
systematically demonstrated that when a patient 
bleeds, this is the first factor to reach really low 
levels, inadequate for the formation of a clot.
One of the first randomized placebo controlled 
clinical trials was designed by Fenger-Erikson for 
patients who underwent radical cystectomy (fi-
brinogen versus placebo). Although the number of 
study participants was low, it was sufficient enough 
to show that the number of blood components 
transfused was significantly lower in the fibrinogen 
group [10]. Several recent studies have shown fibri­
nogen to be beneficial in various clinical situations 
Figure 2. The cell based model of coagulation. Both figures where kindly supplied by CSL Behring
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such as cardiovascular and vascular surgery, ob-
stetric complications, trauma, hepatic surgery, etc. 
A quite recent placebo controlled double blind 
study designed by Rahe-Mayer which included 
61 patients submitted to aortic surgery has proved 
that the number of allogeneic units of red blood cell 
concentrates and fresh frozen plasma transfused in 
the fibrinogen group, was much lower as compared 
to that in placebo group (85% reduction) [11].
The threshold value of serum fibrinogen con-
centration that indicates the need for fibrinogen 
administration, when fibrinogen is measured by the 
Clauss method, is still a matter of discussion and must 
obviously differ according to the clinical situation. 
According to our current knowledge on coagulation 
pathophysiology, it is crucial to remember that fi-
brinogen is of critical importance because it warrants 
effective hemostasis even at low platelet count.
Numerous advantages of fibrinogen over fresh 
frozen plasma and cryoprecipitate have been 
proved in several studies. One such advantage is 
a standardized and well defined fibrinogen content, 
another is a very low volume of the concentrate 
required for transfusion as compared to that of 
blood components [12, 13]. A major disadvantage 
might be the price though calculations reveal that 
it is possible to economize on blood components, 
particularly when fibrinogen administration is 
based on point of care tests used for prompt and 
directed diagnosis [14].
Fibrinogen concentrates have been demon-
strated as effective as well as safe in a wide variety 
of clinical settings, also for the newborns. After 
22 years of pharmacovigilance the assessed risk 
of fibrinogen concentrate therapy is considered to 
be low. Following the experience of the last several 
years we may say that a dose of 30 mg to 50 mg/kg, 
dependent on baseline values and clinical situation, 
is effective and can be repeated. 
Prothrombin complex concentrates (PCC)
Originally PCCs were developed as a source 
of factor IX for Hemophilia B patients and for that 
reason they all contain the same amount of FIX. 
Some differences may however be found in the 
compositions of commercial PCCs. They all con-
tain factors II, VII, IX and X, but may also include 
proteins C, S, AT and heparin. Their impact on 
coagulation is different and depends on the content 
of others factors, especially factor II [4].
The main indications for the use of PCC are 
the need for rapid reversal of anticoagulation in 
a bleeding patient or prior to urgent surgery and 
severe liver disease in patients with prolonged 
clotting time or with active bleeding [15]. A more 
recent indication for the use of PCC is bleeding 
associated with surgery or trauma. These con-
centrates are also used for the reversal of new 
oral anticoagulants. This however is still an issue 
open to discussion.
It should be kept in mind that PCCs might 
be the cause of thromboembolic events which are 
dose-dependent (normally administered is a dose 
of 30 UI/kg). The incidence rate for such thrombo-
embolic events is 2%. It is recommended that each 
hospital develops algorithms to guide haemostatic 
therapy.
In Portugal PCCs have been used for many 
years for reversal of anticoagulation. There is 
a large retrospective study published in 2012 
involving 1152 patients, which deals with PCCs 
used mainly for reversal of anticoagulation and 
has proved them to be safe and effective [16]. The 
use of these concentrates is gradually spreading 
to other clinical situations, such as uncontrolled 
bleeding in the perioperative or trauma setting. 
Our experience with PCC in the bleeding 
setting is mostly associated with administration 
of fibrinogen concentrate following the results of 
point of care tests. However they are not in routine 
use in all Portuguese hospitals.
Recombinant factor VII and FEIBA (aPCC)
These activated concentrates called by-pass 
agents are mostly used for hemophiliac patients 
with inhibitors. Other indications are congenital 
deficiencies. FEIBA concentrates usually con-
tain smaller amounts of FII, IX and X and larger 
amounts of FVII. Recombinant FVIIa is also used in 
the management of acquired hemophilia and Glanz-
mann’s thrombasthenia. It is occasionally used 
as an off label indication in cases of uncontrolled 
bleeding, although data from clinical trials indicate 
that its efficiency is yet unknown or that it is likely 
to be beneficial but associated with thrombotic risk. 
FVIIa is also expensive. 
At the moment therefore there seem to be 
more questions than answers regarding the use 
of FVIIa in the bleeding perioperative setting 
[17]. So FVIIa administration should proceed 
with extreme caution. Prior to use of FVIIa it is 
essential to correct the patient’s parameters such 
as platelet count, fibrinogen, acidosis, hematocrit, 
hypothermia and hypocalcaemia. Once the decision 
for FVIIa administration is made the optimal dose 
to be applied is 90–120 ug/kg.
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Factor XIII
There is some emerging information to sug-
gest the importance of this coagulation factor for 
bleeding patients, especially in the cardiac setting. 
One randomized placebo controlled trial in gas-
trointestinal cancer surgery is also reported. The 
available data seem to suggest the benefits of factor 
XIII in terms of post-operative blood loss. [4]. In 
Portugal factor XIII is used only in major hospitals 
which follow patients with diagnosis of congenital 
factor deficiencies. According to reports it can 
be effectively used in the perioperative bleeding 
setting. However, the data for our country is still 
scarce and more studies are required. 
Other clotting factors and hemostatic 
agents
When a patient is bleeding it is recommended 
to consider other clinical aspects and one of them 
is the development of acquired coagulation factor 
deficiencies such as von Willebrand disease. The 
situation is rare but might occur in patients with 
no history of bleeding. 
It may happen that congenital deficiencies 
are not diagnosed in the preoperative period. 
Therefore it is never too much to emphasize the 
importance of collecting clinical history and per-
forming laboratory tests to diagnose coagulation 
factors deficiency in the case of patients scheduled 
for elective surgery.
There is a natural balance within the hemo-
static system. On the one hand the system protects 
the organism against bleeding. But there is also 
a number of mechanisms that work simultaneously 
to control hemostasis: the fibrinolytic system, 
natural anticoagulants and tissue factor pathway 
inhibitors. It is extremely important to have control 
over the mechanisms referred to above; otherwise 
a premature dissolution of the clot may result in 
prolonged bleeding. 
Tranexamic acid (TXA) may be of special in-
terest in this context. In several trials it has been 
shown to prevent severe bleeding in situations 
prone to premature hyperfibrinolysis. TXA is rou-
tinely used in trauma and cardiovascular surgery 
but has also been found effective in other contexts 
such as obstetric complications and urologic surgery.
Conclusion
To summarize, it may be said that during the 
last decades the understanding of healthcare pro-
fessionals regarding the haemostatic system has 
undergone major revision. As consequence, the 
therapeutic choices in the field of acquired bleed-
ing disorders are shifting from classic non­specific 
therapies to specific plasma factor concentrates. 
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